Future oncology最新文献_第3页

Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary. loncastuximab tesirine后嵌合抗原受体t细胞治疗大b细胞淋巴瘤的实际治疗：一个简单的语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-30 DOI: 10.1080/14796694.2025.2492543

Mehdi Hamadani, Melanie Lucero, Jakob D DeVos, Lei Chen

引用次数: 0

Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma. 健康的社会决定因素对多发性骨髓瘤治疗模式和结果的影响

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-12 DOI: 10.1080/14796694.2025.2498878

Natalie Boytsov, Jasjit K Multani, Zifan Zhou, Nirali Kotowsky, Amanda Bolgioni-Smith, Tianyao Huo, Queenie Paltanwale, Simon McNamara, Chi-Chang Chen

{"title":"Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma.","authors":"Natalie Boytsov, Jasjit K Multani, Zifan Zhou, Nirali Kotowsky, Amanda Bolgioni-Smith, Tianyao Huo, Queenie Paltanwale, Simon McNamara, Chi-Chang Chen","doi":"10.1080/14796694.2025.2498878","DOIUrl":"10.1080/14796694.2025.2498878","url":null,"abstract":"Aims: Evaluate treatment and outcomes by social determinants of health (SDoH) in multiple myeloma (MM), which are important for improving care and outcomes.Methods: This was a retrospective study of real-world patients enrolled in a US insurance claims database (MM diagnosis, July 2018-December 2022) with linkage to a SDoH database, supplemented with mortality, provider affiliation (academic/community), and socioeconomically disadvantaged area databases. Treatment and outcomes were evaluated across SDoH domains: race/ethnicity, education level, transportation access, food insecurity, risky health behaviors, living in disadvantaged areas, healthcare needs, and ease of healthcare-systems engagement.Results: The study included 4768 patients (2295 and 2731 with care-setting and treatment data); median follow-up, 584 days. Patients treated in academic versus community settings were less likely to be food insecure and live in disadvantaged areas and had lower healthcare needs. Stem cell transplant was more common in White versus non-White patients, those with low versus high food insecurity and healthcare needs, and high versus low ease of healthcare-systems engagement. In multivariable analysis, high versus low disadvantaged areas (HR = 1.75) and medium versus low food insecurity (HR = 1.80) were associated with shorter overall survival.Conclusions: These findings indicate a need for improved access to care in the broader MM population.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1663-1673"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC. 雄激素受体信号抑制剂作为一线治疗mCRPC的长期疗效的预后因素。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-04-28 DOI: 10.1080/14796694.2025.2497749

Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi, Giovanni Farinea, Dzenete Kadrija, Stefania Kinspergher, Eleonora Lai, Ludovica Lay, Francesca Maines, Alessia Mennitto, Francesco Pierantoni, Alessandro Samuelly, Susanna Urban, Orazio Caffo, Consuelo Buttigliero

{"title":"Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC.","authors":"Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi, Giovanni Farinea, Dzenete Kadrija, Stefania Kinspergher, Eleonora Lai, Ludovica Lay, Francesca Maines, Alessia Mennitto, Francesco Pierantoni, Alessandro Samuelly, Susanna Urban, Orazio Caffo, Consuelo Buttigliero","doi":"10.1080/14796694.2025.2497749","DOIUrl":"10.1080/14796694.2025.2497749","url":null,"abstract":"Aim: Androgen receptor signaling inhibitors (ARSI) demonstrated to be efficacious as first-line therapy for mCRPC. The present real-world study aimed to identify the characteristics of the long-term responders (LTR) patients to first-line ARSI.Methods: We retrospectively reviewed a consecutive series of 622 mCRPC patients treated with one ARSI as first line. Patients received standard doses of abiraterone (1000 mg daily plus prednisone 10 mg daily) or enzalutamide (160 mg daily) until progression. Patients with an ARSI exposure ≥ 36 months were considered as LTR.Results: We identified 99 LTR patients who were compared to 523 no-LTR patients. At the multivariable analysis, LTR patients showed younger age (p < 0.0001), longer time to mCRPC (p < 0.0001), higher baseline levels of hemoglobin (p = 0.007), lower baseline PSA levels (p = 0.03), longer PSA doubling time (p = 0.03), low number of bone metastases (p = 0.01), and receivedenzalutamide (p = 0.01). The median overall survival (OS) of LTR was 78.2 months (95% CI 72.3-84.1 months) vs 27.7 months of no-LTR (95% CI 25.9-29.6 months).Conclusions: Several clinical and biological factors allow to identify those patients with higher probability of becoming LTR to ARSI in first-line mCRPC setting.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1647-1653"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of PERMA-based psychological intervention and predictive care in malignant tumor patients following chemotherapy. 基于permaar的心理干预及预测性护理在恶性肿瘤患者化疗后的效果。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI: 10.1080/14796694.2025.2497257

Xiuying Hu, Qiuyue Li, Liying Tang

{"title":"Effect of PERMA-based psychological intervention and predictive care in malignant tumor patients following chemotherapy.","authors":"Xiuying Hu, Qiuyue Li, Liying Tang","doi":"10.1080/14796694.2025.2497257","DOIUrl":"10.1080/14796694.2025.2497257","url":null,"abstract":"Background: Alleviating the toxic and adverse reactions associated with chemotherapy is crucial for improving patient outcomes. This study aimed to assess the impacts of positive emotion, engagement, relationships, meaning, and accomplishment (PERMA) model-based psychological interventions and predictive chemotherapy reaction nursing on patients with malignant tumors following chemotherapy.Research design and methods: The control group (n = 43) received conventional care, while the observation group (n = 43) received psychological intervention based on PERMA model alongside predictive nursing care. Chemotherapy-induced toxicity and side effects, fatigue levels, coping mode, psychological status, and quality of life were assessed.Results: Compared to the control group, the observation group exhibited a lower incidence of gastrointestinal adverse reactions, myelosuppression, alopecia, and oral ulcers (p < 0.05), reduced behavioral, cognitive, somatic, and emotional fatigue (p < 0.001), lower scores in avoidance and yielding coping styles (p < 0.001), higher scores in confrontation coding mode (p = 0.056), improved quality of life, and better outcomes in anxiety, depression, and overall psychological state of patients (p < 0.001).Conclusion: PERMA model-based psychological interventions and predictive chemotherapy reaction nursing interventions effectively reduce the incidence of chemotherapy-induced toxicity, alleviate fatigue, enhance quality of life, and improve psychological well-being in cancer patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1639-1645"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study. 在嵌合抗原受体t细胞治疗弥漫性大b细胞淋巴瘤后，loncastuximab tesirine的疗效如何？对真实世界证据研究的简单语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-29 DOI: 10.1080/14796694.2025.2504802

Narendranath Epperla, Melanie Lucero, Tom Bailey, Laura Mirams, Jolenta Cheung, Mona Amet, Gary Milligan, Lei Chen

引用次数: 0

Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study. 胃肠道间质瘤伴淋巴结转移的临床特征：一项回顾性单中心研究。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1080/14796694.2025.2499431

Xiaodan Guo, Shaoqing Huang, Shaohua Yang, Yanzhe Xia, Chunhui Wu, Shirong Cai, Yulong He, Xuefu Zhou, Xinhua Zhang

{"title":"Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study.","authors":"Xiaodan Guo, Shaoqing Huang, Shaohua Yang, Yanzhe Xia, Chunhui Wu, Shirong Cai, Yulong He, Xuefu Zhou, Xinhua Zhang","doi":"10.1080/14796694.2025.2499431","DOIUrl":"10.1080/14796694.2025.2499431","url":null,"abstract":"Background: Lymph node metastasis (LNM) of gastrointestinal stromal tumors (GISTs) rarely occurs, and lymphadenectomy is not routinely performed in GIST resection. To date, the relevant characteristics and prognosis of GIST patients with LNM are not well known.Methods: From January 2010 to December 2021, GIST patients who underwent lymph node resection were enrolled from a GIST referral center. All patients were divided into either the LN- group (GISTs without LNM) or the LN+ group (GISTs with LNM). The clinicopathological features and follow-up data were analyzed. Propensity score matching (PSM) was conducted to reduce bias caused by confounders.Results: Out of 1024 surgical patients, 198 patients (age, 52.23 ± 13.54 years; 56.6% males) underwent GIST resection with lymph node dissection for lymphadenopathy, and 17 patients had lymph node metastases (17/1024, 1.66%; 17/198, 8.59%). The LN+ group had a higher mitotic count (p = 0.012) and a higher proportion of distant metastasis (p < 0.001) than the LN- group. After PSM, 28 patients were included (18 in LN- group and 10 in LN+ group). The LN- group had both longer postoperative progression-free survival (PFS, not reached vs. 15.0 months, p = 0.002) and overall survival (OS) than the LN+ group, but the difference in OS was not statistically significant (not reached vs. 35.0 months, p = 0.069).Conclusions: The rate of LNM in GISTs is low. LNM may be a less common form of distant metastasis. Moreover, GIST with LNM has an unfavorable prognosis. Further studies are warranted to identify GISTs with lymph node involvement and the potential involved mechanism.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1655-1662"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS). nivolumab再给药治疗晚期胃癌（NIVO RETURNS）的多中心、前瞻性、观察性研究。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1080/14796694.2025.2500918

Hiroyuki Kodama, Yukiya Narita, Michio Nakamura, Masanobu Takahashi, Takuro Mizukami, Takayuki Ando, Seiichiro Mitani, Azusa Komori, Ayumu Hosokawa, Toshikazu Moriwaki, Keiji Sugiyama, Masataka Taguri, Shunichiro Orihara, Hiroshi Kagamu, Toshifumi Yamaguchi, Hiroki Nishikawa, Kei Muro

{"title":"A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS).","authors":"Hiroyuki Kodama, Yukiya Narita, Michio Nakamura, Masanobu Takahashi, Takuro Mizukami, Takayuki Ando, Seiichiro Mitani, Azusa Komori, Ayumu Hosokawa, Toshikazu Moriwaki, Keiji Sugiyama, Masataka Taguri, Shunichiro Orihara, Hiroshi Kagamu, Toshifumi Yamaguchi, Hiroki Nishikawa, Kei Muro","doi":"10.1080/14796694.2025.2500918","DOIUrl":"10.1080/14796694.2025.2500918","url":null,"abstract":"Combination treatment with an anti-programmed cell death-1 (PD-1) antibody, an immune checkpoint inhibitor (ICI), and chemotherapy is the standard treatment for patients with HER2-negative advanced gastric/esophagogastric cancer (AGC). ICI re-administration has been reported to have a clinical benefit for patients with lung cancer or melanoma. However, data on patients with AGC have not yet been collected. We plan to conduct a prospective, multicenter, observational NIVO RETURNS study to evaluate the efficacy and safety of nivolumab monotherapy re-administration in patients with AGC refractory to initial anti-PD-1 or anti-programmed cell death ligand-1 (PD-L1) antibody treatment. Patients who have achieved clinical benefits (complete response, partial response, or stable disease for ≥ 6 months) from prior treatment, including anti-PD-1/PD-L1 therapy, will be included. The primary endpoint will be the objective response rate to nivolumab re-administration. We anticipate that our findings will contribute to the improvement of survival outcomes as later-line treatment for AGC.Clinical trial registration: UMIN000050515, UMIN000051044.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1753-1759"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients. 多米尼卡：多斯塔利单抗与化疗单独治疗一线mmr缺陷晚期子宫内膜癌患者

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1080/14796694.2025.2496133

François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, Domenica Lorusso, Chel Hun Choi, Kosei Hasegawa, David Shao Peng Tan, Emma Hudson, Alison Davis, Germana Tognon, Stéphanie Lheureux, Mehmet Ali Vardar Key, Jean Emmanuel Kurtz, Jerome Alexandre, Florence Joly

{"title":"DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.","authors":"François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, Domenica Lorusso, Chel Hun Choi, Kosei Hasegawa, David Shao Peng Tan, Emma Hudson, Alison Davis, Germana Tognon, Stéphanie Lheureux, Mehmet Ali Vardar Key, Jean Emmanuel Kurtz, Jerome Alexandre, Florence Joly","doi":"10.1080/14796694.2025.2496133","DOIUrl":"10.1080/14796694.2025.2496133","url":null,"abstract":"Immunotherapy (IO) in endometrial cancer (EC) is the standard of care in the second line setting in combination with an anti-angiogenic agent. Randomized clinical trials have reported results supporting the addition of IO to chemotherapy (paclitaxel plus carboplatin) in the first-line setting in advanced EC patients in the global population, with high efficacy in mismatch repair deficient (MMRd) patients. These trials were not designed to answer this de-escalation question in the MMRd population, who benefit greatly from IO.The international, randomized phase III, DOMENICA trial compares first-line dostarlimab versus chemotherapy alone (with planned cross-over) for advanced MMRd EC. Our primary endpoint will be progression-free survival. The key secondary endpoints will be overall survival, safety and quality of life [NCT05201547].","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1613-1623"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access. 克服障碍的先进生物分子技术，告知治疗实体瘤：路线图获取。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1080/14796694.2025.2501523

Jesús Garcia-Foncillas, Arnaud Bayle, Dirk Arnold, Bernard Avouac, Ahmad Awada, Luis de la Cruz-Merino, Åslaug Helland, Ulrik Lassen, Pierre Laurent-Puig, Nicola Normanno, Kristoffer Rohrberg, Julien Taieb, Albrecht Stenzinger

{"title":"Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access.","authors":"Jesús Garcia-Foncillas, Arnaud Bayle, Dirk Arnold, Bernard Avouac, Ahmad Awada, Luis de la Cruz-Merino, Åslaug Helland, Ulrik Lassen, Pierre Laurent-Puig, Nicola Normanno, Kristoffer Rohrberg, Julien Taieb, Albrecht Stenzinger","doi":"10.1080/14796694.2025.2501523","DOIUrl":"10.1080/14796694.2025.2501523","url":null,"abstract":"The advent of advanced biomolecular technologies for detecting molecular and genomic signatures of individual tumors has transformed oncology care, introducing proven methodologies that can inform treatment with matched targeted therapies and predict response at the individual patient level. However, access to these technologies has been hampered by multiple barriers, most notably price and obtainability. Other barriers include lack of knowledge of available technologies, concerns about value, and outdated infrastructures that impede critical operations within the clinic or laboratory. Accessibility barriers to advanced biomolecular testing are critically important to patient care, as new technological advances in molecular medicine continue to outpace the implementation of solutions. Given the proven evidence for improved patient outcomes with precision oncology medicines, it is imperative to understand the value afforded by these technologies. The purpose of this narrative review is to describe existing and emerging barriers to access and present a \"roadmap to access\" that will facilitate the urgently needed discussions to identify solutions for improving access. Implementation of these solutions will raise awareness of available technologies and treatments and their prognostic significance, improve evidence collection for demonstration of value, and fortify clinical and laboratory infrastructure and operations.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1745-1752"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy. 意大利含西妥昔单抗治疗头颈部鳞状细胞癌的成本-效果

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-18 DOI: 10.1080/14796694.2025.2503667

Philipp Ivanyi, Ash Bullement, Andrea Botticelli, Francesco Perri, Giorgio L Colombo, Viviana Annibali, Anita Gandola, Jaesh Naik, Michael Schlichting, Chris P Pescott

{"title":"Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy.","authors":"Philipp Ivanyi, Ash Bullement, Andrea Botticelli, Francesco Perri, Giorgio L Colombo, Viviana Annibali, Anita Gandola, Jaesh Naik, Michael Schlichting, Chris P Pescott","doi":"10.1080/14796694.2025.2503667","DOIUrl":"10.1080/14796694.2025.2503667","url":null,"abstract":"Aims: To investigate the differences in clinical outcomes and costs for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) with a combined positive score (CPS) of 1-19, with pembrolizumab ± chemotherapy or a cetuximab-containing regimen (CCR) in Italy.Methods: A naïve indirect treatment comparison was conducted, and outcomes were incorporated into a newly developed cost-utility model. Inputs were derived from clinical trials, technology appraisal reports, and published literature. Scenario analyses were undertaken to explore key areas of uncertainty.Results: Across the comparisons of pembrolizumab ± chemotherapy versus CCRs, incremental life-years ranged from - 0.502 to 0.155, while incremental quality-adjusted life years (QALYs) ranged from - 0.379 to 0.085. In some scenarios, CCRs dominated pembrolizumab ± chemotherapy (i.e. more QALYs at lower costs). In others, CCRs yielded similar estimates of QALYs at lower costs.Conclusion: CCRs are likely to represent a comparable or more effective treatment option compared to pembrolizumab ± chemotherapy. Model results consistently demonstrated that CCRs are a cost-effective treatment strategy. CCRs remain a relevant treatment option for R/M SCCHN and a CPS of 1-19, for whom a targeted, patient-focused approach is warranted.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1779-1786"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0